CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Alumis Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Alumis Inc
280 East Grand Avenue
Phone: (650) 231-6625p:650 231-6625 SOUTH SAN FRANCISCO, CA  94080  United States Ticker: ALMSALMS
Business Summary
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202512/31/2024YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer MartinBabler 59 9/1/2021 9/1/2021
Chief Financial Officer John R.Schroer 58 5/1/2022 5/1/2022
Senior Vice President - People and Culture DerrickRichardson 54 6/1/2023 6/1/2023
11 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
ACELYRIN Inc 4149 Liberty Canyon Road AGOURA HILLS CA United States
Valenzabio, Inc. 6701 Democracy Blvd. Suite 300. Bethesda MD United States

Business Names
Business Name
ACELYRIN Inc
ALMS
ALUMIS INC
Valenzabio, Inc.

General Information
Number of Employees: 182 (As of 3/31/2025)
Outstanding Shares: 103,004,632 (As of 5/21/2025)
Stock Exchange: NASD
Fax Number: (302) 531-3150
Email Address: info@alumis.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, May 23, 2025